» Articles » PMID: 38556557

Genetic Contribution to Disease-course Severity and Progression in the SUPER-Finland Study, a Cohort of 10,403 Individuals with Psychotic Disorders

Abstract

Genetic factors contribute to the susceptibility of psychotic disorders, but less is known how they affect psychotic disease-course development. Utilizing polygenic scores (PGSs) in combination with longitudinal healthcare data with decades of follow-up we investigated the contributing genetics to psychotic disease-course severity and diagnostic shifts in the SUPER-Finland study, encompassing 10 403 genotyped individuals with a psychotic disorder. To longitudinally track the study participants' past disease-course severity, we created a psychiatric hospitalization burden metric using the full-coverage and nation-wide Finnish in-hospital registry (data from 1969 and onwards). Using a hierarchical model, ranking the psychotic diagnoses according to clinical severity, we show that high schizophrenia PGS (SZ-PGS) was associated with progression from lower ranked psychotic disorders to schizophrenia (OR = 1.32 [1.23-1.43], p = 1.26e-12). This development manifested already at psychotic illness onset as a higher psychiatric hospitalization burden, the proxy for disease-course severity. In schizophrenia (n = 5 479), both a high SZ-PGS and a low educational attainment PGS (EA-PGS) were associated with increased psychiatric hospitalization burden (p = 1.00e-04 and p = 4.53e-10). The SZ-PGS and the EA-PGS associated with distinct patterns of hospital usage. In individuals with high SZ-PGS, the increased hospitalization burden was composed of longer individual hospital stays, while low EA-PGS associated with shorter but more frequent hospital visits. The negative effect of a low EA-PGS was found to be partly mediated via substance use disorder, a major risk factor for hospitalizations. In conclusion, we show that high SZ-PGS and low EA-PGS both impacted psychotic disease-course development negatively but resulted in different disease-course trajectories.

Citing Articles

General medical comorbidities in psychotic disorders in the Finnish SUPER study.

Ahti J, Kieseppa T, Haaki W, Suvisaari J, Niemela S, Suokas K Schizophrenia (Heidelb). 2024; 10(1):124.

PMID: 39741144 PMC: 11688420. DOI: 10.1038/s41537-024-00546-1.

References
1.
Zammit S, Allebeck P, David A, Dalman C, Hemmingsson T, Lundberg I . A longitudinal study of premorbid IQ Score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. Arch Gen Psychiatry. 2004; 61(4):354-60. DOI: 10.1001/archpsyc.61.4.354. View

2.
Haywood T, Kravitz H, Grossman L, Cavanaugh Jr J, Davis J, Lewis D . Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry. 1995; 152(6):856-61. DOI: 10.1176/ajp.152.6.856. View

3.
Ni G, Zeng J, Revez J, Wang Y, Zheng Z, Ge T . A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts. Biol Psychiatry. 2021; 90(9):611-620. PMC: 8500913. DOI: 10.1016/j.biopsych.2021.04.018. View

4.
Goncalves-Pinho M, Braganca M, Freitas A . Psychotic disorders hospitalizations associated with cannabis abuse or dependence: A nationwide big data analysis. Int J Methods Psychiatr Res. 2019; 29(1):e1813. PMC: 7051837. DOI: 10.1002/mpr.1813. View

5.
Zhang Q, Prive F, Vilhjalmsson B, Speed D . Improved genetic prediction of complex traits from individual-level data or summary statistics. Nat Commun. 2021; 12(1):4192. PMC: 8263809. DOI: 10.1038/s41467-021-24485-y. View